Engine Biosciences has secured a $27 million extension to their Series A financing, boosting their total raised funds to $86 million. This Singapore and California-based biotech firm is pushing the boundaries of cancer treatment using a fusion of machine learning and advanced biology.

Leading the investment is Polaris Partners, alongside ClavystBio, Invus, and EDBI, plus fresh investors. The capital infusion is aimed at propelling their precision oncology programs forward, potentially marking a significant advancement in personalized medicine.